GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » PB Ratio

F-star Therapeutics (F-star Therapeutics) PB Ratio : 2.75 (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-06), F-star Therapeutics's share price is $7.12. F-star Therapeutics's Book Value per Share for the quarter that ended in Sep. 2022 was $2.59. Hence, F-star Therapeutics's PB Ratio of today is 2.75.

The historical rank and industry rank for F-star Therapeutics's PB Ratio or its related term are showing as below:

FSTX' s PB Ratio Range Over the Past 10 Years
Min: 0.57   Med: 1.84   Max: 3.36
Current: 2.75

During the past 3 years, F-star Therapeutics's highest PB Ratio was 3.36. The lowest was 0.57. And the median was 1.84.

FSTX's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.505 vs FSTX: 2.75

During the past 12 months, F-star Therapeutics's average Book Value Per Share Growth Rate was -40.70% per year.

Back to Basics: PB Ratio


F-star Therapeutics PB Ratio Historical Data

The historical data trend for F-star Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics PB Ratio Chart

F-star Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
PB Ratio
- 2.09 1.08

F-star Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.08 0.87 1.89 1.98

Competitive Comparison of F-star Therapeutics's PB Ratio

For the Biotechnology subindustry, F-star Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


F-star Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's PB Ratio falls into.



F-star Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

F-star Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2022)
=7.12/2.59
=2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


F-star Therapeutics  (NAS:FSTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


F-star Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


F-star Therapeutics (F-star Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Executives
Geoffrey Race director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks officer: See Remarks C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster director, officer: PRESIDENT AND CEO C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire officer: CHIEF MEDICAL OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis officer: CHIEF SCIENTIFIC OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein director 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik director GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow officer: General Counsel and Secretary 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani officer: VP of Finance and Treasurer 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon director, 10 percent owner 86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116

F-star Therapeutics (F-star Therapeutics) Headlines

From GuruFocus